Blogs | Multibagger Shares

April 30, 2026

Hero Banner for return on Capital Employed roce Article with a Centered Circular Fy25 Chart on a Dark Blue Background Top Branding Visible

Return on Capital Employed (RoCE): The Single Most Important Profitability Metric for Indian Value Investors

Buffett calls RoCE the single most important number in business analysis. This educational deep-dive explains the formula, the Indian thresholds, the five common traps, and applies it to Titan Biotech FY25's audited markers.

April 30, 2026

Hero Section Title second level Thinking with Subtitle Dark Blue Background and a Four block Grid Labeled Trader gray Compounder green Drift light Gray Speculator orange

Second-Level Thinking: Howard Marks’s First-Chapter Discipline for Indian Value Investors

Howard Marks's most important idea: investing edge is built by going beyond the surface reaction. A practical three-habit discipline, illustrated with Titan Biotech's FY25 audited numbers.

April 29, 2026

Hero Header with Title Representativeness Heuristic and Subtitle a 2x2 Color Infographic Showing Lucky gray Disciplined Investor green Confused light Gray Bias trapped orange

Representativeness Heuristic: Why Indian Investors Confuse “Looks Like the Next Multibagger” with Probability

The representativeness heuristic — Kahneman & Tversky's 1972 framework — explains why Indian retail investors keep paying for stocks that resemble past multibaggers but don't share the underlying base-rate process markers. Titan Biotech FY25 illustrates the opposite — process over pattern.

April 29, 2026

Hero Banner Title capex to depreciation Ratio with Green Accent Marks and a Circular Fy25 Infographic on a Dark Blue Gradient Background Subtitle Mentions Reinvestment Discipline

Capex-to-Depreciation Ratio: The 60-Second Reinvestment-Discipline Filter Every Indian Value Investor Must Master

The Capex-to-Depreciation Ratio is the cleanest 60-second filter for whether a business is genuinely reinvesting (above 1.0x) or quietly harvesting (below 1.0x). Titan Biotech FY25 audited numbers — ~Rs.11 Cr CWIP, ~Rs.57 Cr gross block, ~7% depreciation/gross block, ~103% CFO/Operating Profit and only ~Rs.3 Cr total borrowings — illustrate disciplined, internally funded reinvestment. Educational illustration; not a buy/sell recommendation.